Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
View Older Stories
-
Blueprint Medicines (BPMC) Enters $1.25B Strategic Financing Collaborations with Sixth Street and Royalty Pharma (RPRX)
-
Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma
-
Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results
-
Blueprint Medicines to Present at Upcoming Investor Conferences
-
Blueprint Medicines (BPMC) Gavreto Reaches 25% NRX Share - Cowen
-
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
-
Blueprint Medicines to Present at Upcoming Investor Conferences
-
Blueprint Medicines (BPMC) Prices 4.71M Share Common Offering at $69/Sh
-
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
-
Blueprint Medicines (BPMC) Announces Proposed $325M Public Offering of Shares of Common Stoc
-
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
-
Blueprint Medicines (BPMC) Reiterated Outperform at Cowen
-
Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
-
Blueprint Medicines (BPMC) Prices 4.054M Share Common Offering at $74/Sh
-
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
-
Blueprint Medicines (BPMC) to Offer $300M in Stock
-
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
-
Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference
-
Blueprint Medicines to Present at Cowen and Company 38th Annual Health Care Conference
-
Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
-
Blueprint Medicines (BPMC) Prices 3.7M Share Offering at $81/Sh
-
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
-
Blueprint Medicines (BPMC) to Offer $275M in Common Stock
-
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
-
Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
-
Blueprint Medicines (BPMC) Prices 5M Shares at $40
-
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
-
Blueprint Medicines (BPMC) Commences $150M Offering of Common Stock
-
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
-
Blueprint Medicines to Present at Upcoming Investor Conferences in March
-
Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
-
Blueprint Medicines (BPMC) Prices $125M Common Stock Offering
-
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
-
Blueprint Medicines (BPMC) to Offer $125M of Common Stock
-
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
-
Blueprint Medicines to Present at Cowen and Company 36th Annual Health Care Conference
-
Cowen Starts Blueprint Medicines (BPMC) at Outperform
-
Blueprint Medicines Announces Closing of Initial Public Offering
-
Blueprint Medicines (BPMC) IPO Opens Up 30%
-
Blueprint Medicines Announces Pricing of Initial Public Offering
-
Blueprint Medicines Files Registration Statement for Proposed Initial Public Offering
-
Blueprint Medicines (BPMC) Files $100M IPO

